GSK3A/GSK3B Antibody

What are GSK3A and GSK3B, and why are specific antibodies important for studying them?

GSK3A and GSK3B (Glycogen Synthase Kinase 3 alpha and beta) are serine/threonine kinases encoded by distinct genes that share 98% identity within their kinase domains. Despite their similarities, they perform both overlapping and unique functions depending on cell type and differentiation status .

Specific antibodies are crucial because:

• They enable discrimination between the two highly similar isoforms

• They can distinguish between active (nonphosphorylated) and inactive (phosphorylated) forms

• They allow for precise localization studies within cells and tissues

• They enable functional studies of each isoform's distinct roles

Methodologically, researchers should select antibodies that target unique epitopes between the isoforms or specifically recognize post-translational modifications like the inhibitory phosphorylation at Ser9 (GSK3B) or Ser21 (GSK3A) .

How do antibodies distinguish between active and inactive forms of GSK3?

GSK3 activity is primarily regulated through phosphorylation of N-terminal serine residues (S9 in GSK3β, S21 in GSK3α). This phosphorylation is inhibitory, as the phosphorylated N-terminus acts as a competitive inhibitor for primed substrates .

Antibodies can distinguish these states through:

• Phospho-specific antibodies that recognize only the phosphorylated serine residues

• Non-phospho-specific antibodies that recognize only the nonphosphorylated (active) form

For example, the monoclonal antibody 12B2 specifically reacts with nonphospho-S9 GSK3β but not with phospho-S9 GSK3β or any form of GSK3α. Similarly, the 15C2 antibody recognizes both nonphospho-S9 GSK3β and nonphospho-S21 GSK3α but does not react with their phosphorylated counterparts .

To validate antibody specificity, researchers can use dephosphorylation treatments with alkaline phosphatase or induce phosphorylation with kinases like Akt1 .

What applications are GSK3A/GSK3B antibodies suitable for in research?

GSK3A/GSK3B antibodies support multiple applications depending on their characteristics and validation:

• Western blotting (WB): Most antibodies are validated for WB, enabling detection of GSK3 isoforms and their phosphorylation status in cell or tissue lysates .

• Immunoprecipitation (IP): Some antibodies effectively immunoprecipitate GSK3 proteins. For instance, 12B2 specifically pulls down GSK3β while 15C2 pulls down both GSK3α and β isoforms .

• Immunofluorescence (IF) and Immunohistochemistry (IHC): Many antibodies work in IF and IHC applications, revealing subcellular localization. Antibodies like 12B2 typically produce stronger punctate staining patterns compared to others .

• ELISA: Select antibodies are validated for ELISA applications, enabling quantitative assessment of GSK3 levels .

Researchers should verify the specific applications validated for their chosen antibody and consider the species reactivity, which commonly includes human, mouse, and rat .

How do GSK3A and GSK3B distributions differ across cell types and how can antibodies help visualize these differences?

GSK3A and GSK3B show distinct subcellular distribution patterns that vary across cell types:

In human spermatozoa:

• GSK3A is primarily located in the flagellum (98.0%) with 75.7% of cells also showing immunoreactivity in the head. Notably, 24.2% of spermatozoa demonstrate strong GSK3A immunoreactivity in the equatorial region .

• GSK3B is mainly located in the sperm head (97.0%), with only 23.9% of sperm showing GSK3B distributed throughout the entire head and flagellum .

In cultured cells:

• Both isoforms typically show punctate staining patterns, but with different intensities and distributions .

• In HEK293T cells, SH-SY5Y cells, and primary neurons, GSK3B-specific antibodies (like 12B2) generally produce stronger staining compared to antibodies that detect both isoforms (like 15C2) .

In brain tissue:

• Both antibodies produce clear somatodendritic and parenchymal staining in human and rat brain sections .

Methodologically, researchers should use isoform-specific antibodies for co-staining experiments with counterstains for cellular compartments (e.g., phalloidin for cytoskeleton) to accurately map the distribution of each isoform .

What controls should I include when using GSK3A/GSK3B antibodies in experimental procedures?

When using GSK3A/GSK3B antibodies, several controls are essential to ensure valid and interpretable results:

For Western Blotting:

• Positive control: Cell lysates known to express the target protein (e.g., HEK293T cells for GSK3β)

• Negative control: Knockout cell lines when available, or siRNA-treated samples

• Phosphorylation controls:

  • Samples treated with alkaline phosphatase to dephosphorylate S9/S21

  • Samples treated with Akt1 to increase phosphorylation at S9/S21

• Loading control: GAPDH or similar housekeeping protein

For Immunofluorescence:

• Primary antibody deletion: Staining without the primary antibody to assess background from secondary antibody

• Peptide competition: Pre-incubation of antibody with immunizing peptide to confirm specificity

• Counterstaining: With total GSK3α/β antibody and nuclear stain (DAPI) to confirm localization patterns

For Immunoprecipitation:

• Non-immune IgG control: Mouse or rabbit IgG depending on the antibody species to assess non-specific binding

• Input sample: To compare with immunoprecipitated material

• Post-IP lysate: To evaluate pull-down efficiency

These controls help validate specificity and rule out technical artifacts that could lead to misinterpretation of results.

How does GSK3 phosphorylation status correlate with cellular functions and how can this be measured?

GSK3 phosphorylation status directly correlates with its kinase activity and downstream biological effects:

Correlation with function:

• Non-phosphorylated GSK3 (at S9/S21) represents the active form that phosphorylates downstream targets including glycogen synthase, β-catenin, tau protein, and transcription factors

• Phosphorylation at S9 (GSK3β) or S21 (GSK3α) inhibits kinase activity by creating a competitive pseudosubstrate that blocks the catalytic site

• In sperm, GSK3A phosphorylation status shows a significant negative correlation with progressive motility (r = 0.822, P = 0.023), whereas inhibited GSK3B does not significantly correlate with sperm motility

Measurement techniques:

• Western blotting: Using antibodies that specifically recognize phosphorylated or non-phosphorylated forms

  • Anti-pS9 GSK3β antibodies detect the inactive form

  • Antibodies like 12B2 (for GSK3β) and 15C2 (for both isoforms) detect the active non-phosphorylated forms

• Kinase activity assays: Using recombinant substrates to directly measure GSK3 activity in immunoprecipitates

• Cellular functional assays: Measuring downstream effects like:

  • Glycogen synthesis rates

  • β-catenin stabilization/degradation

  • Tau phosphorylation levels

For accurate assessment, researchers should combine these approaches, using antibodies that distinguish between phosphorylated and non-phosphorylated forms alongside functional readouts of GSK3 activity .

How can I validate GSK3A/GSK3B antibody specificity for my experimental system?

Comprehensive validation of GSK3A/GSK3B antibodies requires multiple complementary approaches:

Genetic validation:

• Knockout/knockdown systems: Use CRISPR/Cas9 knockout or siRNA knockdown of GSK3A or GSK3B to confirm antibody specificity. For example, wild-type and GSK3β knockout HeLa extracts can be compared by Western blot to confirm signal specificity .

• Overexpression systems: Express tagged versions of GSK3A/B to verify antibody detection against elevated protein levels.

Biochemical validation:

• Peptide competition assays: Pre-incubate antibody with increasing concentrations of immunizing peptide to demonstrate specific blocking of signal.

• Epitope mapping: Use synthetic peptides covering different regions of GSK3A/B to identify the exact binding epitope.

• Phosphatase treatment: Treat samples with alkaline phosphatase to remove phosphorylation and confirm phospho-specificity .

• Kinase treatment: Incubate with Akt1 to increase S9/S21 phosphorylation and confirm phospho-specific detection .

Cross-platform validation:

• ELISA: Perform indirect ELISAs with GSK3 peptides to determine binding affinity and specificity .

• Immunoprecipitation-Mass Spectrometry: Confirm that immunoprecipitated proteins are indeed GSK3A/B through mass spectrometry.

• Cross-reactivity testing: Test against similar kinases to confirm isoform specificity.

Species validation:

• Test antibody reactivity across species relevant to your research (human, mouse, rat) as conservation varies .

Document all validation steps systematically, as different applications (WB, IF, IP) may show varying specificity profiles with the same antibody.

What approaches enable discrimination between isoform-specific functions of GSK3A versus GSK3B?

Discriminating between GSK3A and GSK3B functions requires strategic approaches that overcome their high sequence homology:

Genetic approaches:

• Isoform-specific knockdown: Use siRNA or shRNA targeting unique regions (often in untranslated regions) of GSK3A or GSK3B mRNAs.

• Selective knockout models: Generate conditional knockout models for each isoform separately to avoid developmental complications.

• Rescue experiments: After knockdown/knockout of both isoforms, reintroduce one isoform at a time to identify unique functions.

Pharmacological approaches:

• Isoform-selective inhibitors: While challenging, some compounds show preference for one isoform over the other.

• Activity-biased analysis: Combine pan-GSK3 inhibitors with isoform-specific antibodies to correlate effects with specific isoform activity levels.

Biochemical approaches:

• Isoform-specific immunoprecipitation: Use antibodies like 12B2 (GSK3β-specific) to selectively immunoprecipitate one isoform for activity or interactome studies .

• Interactome analysis: Identify isoform-specific binding partners through mass spectrometry after selective immunoprecipitation .

Localization studies:

• Subcellular distribution analysis: Use isoform-specific antibodies to map differential localization, as seen in sperm where GSK3A predominates in the flagellum while GSK3B is mainly in the head .

• Proximity labeling: Employ BioID or APEX2 fused to each isoform to identify proximity partners in specific cellular compartments.

Functional readouts:

• Isoform-specific correlation analysis: Correlate the activity/levels of each isoform with functional outcomes, as demonstrated in sperm motility studies where GSK3A but not GSK3B phosphorylation correlates with progressive motility .

• Substrate phosphorylation patterns: Identify differential substrate preferences between isoforms.

How do GSK3A and GSK3B contribute differentially to disease pathology and how can antibodies help investigate this?

GSK3A and GSK3B play distinct roles in various disease pathologies that can be investigated using isoform-specific antibodies:

Neurodegenerative diseases:

• Alzheimer's disease: GSK3B phosphorylates tau protein at multiple sites, contributing to neurofibrillary tangle formation . Antibodies can:

  • Quantify isoform-specific levels in patient samples

  • Assess colocalization with phosphorylated tau in brain sections

  • Track changes in GSK3 phosphorylation status in disease progression

Cancer:

• Drug resistance: Both GSK3A and GSK3B regulate drug resistance in cancer cells, though with some differences .

  • Research shows GSK3A is redundant with GSK3B in modulating drug resistance and chemotherapy-induced necroptosis

  • Antibodies can track isoform-specific activation in resistant versus sensitive cell lines

  • Phosphorylation-specific antibodies can monitor therapeutic effects of GSK3 inhibition

Reproductive biology:

• Sperm motility: GSK3A activity negatively correlates with human sperm motility, while GSK3B shows no significant correlation .

  • Antibodies revealing differential distribution (GSK3A in flagellum, GSK3B in head) help explain functional differences

  • Phosphorylation-specific antibodies can assess activation status in relation to fertility markers

Metabolic disorders:

• Insulin resistance: GSK3 isoforms differentially contribute to insulin signaling and glycogen synthesis .

  • Antibodies can monitor tissue-specific changes in GSK3 isoform expression and phosphorylation in diabetic models

Methodological approaches:

• Comparative immunohistochemistry: Using isoform-specific antibodies on disease tissue arrays

• Phosphorylation profiling: Using phospho-specific antibodies to track activation status during disease progression

• Proximity ligation assays: To detect isoform-specific interactions with disease-relevant proteins

• Patient sample analysis: Correlating isoform levels/activation with clinical outcomes

• Drug response monitoring: Tracking GSK3 isoform-specific activity changes during treatment

These approaches enable correlation of isoform-specific functions with disease mechanisms and potential therapeutic interventions.

What are the best practices for troubleshooting contradictory results with different GSK3 antibodies?

When facing contradictory results with different GSK3 antibodies, implement this systematic troubleshooting approach:

Characterize antibody properties:

• Epitope mapping: Identify precise epitopes recognized by each antibody. Antibodies targeting different regions may give different results due to:

  • Conformation-dependent accessibility

  • Post-translational modifications

  • Protein-protein interactions masking epitopes

• Validation history: Review validation data for each antibody, including knockout/knockdown controls

Analyze technical variables:

• Sample preparation effects:

  • Different lysis buffers may preserve or disrupt certain epitopes

  • Fixation methods for IF/IHC can affect epitope accessibility

  • Phosphatase activity during sample preparation can alter phosphorylation detection

• Detection methods:

  • Primary-secondary antibody compatibility

  • Signal amplification differences

  • Differential sensitivity of various visualization methods

Conduct side-by-side comparisons:

• Multi-antibody Western blot: Run identical samples on parallel blots or strip and reprobe

• Immunofluorescence co-staining: When possible, use differently-labeled secondaries to compare staining patterns

• Antibody dilution series: Test a range of concentrations to rule out non-specific binding at high concentrations

Perform validation experiments:

• Phosphatase treatment: Treat samples with alkaline phosphatase to verify phospho-specific antibodies

• Kinase treatment: Treat with Akt1 to increase phosphorylation for phospho-antibodies

• Genetic manipulation: Use siRNA or CRISPR knockout samples as definitive controls

• Peptide competition: Pre-absorb antibodies with specific peptides to confirm binding specificity

Integrate multiple methods:

• Combine antibody-based detection with mass spectrometry

• Correlate antibody results with functional assays of GSK3 activity

• Use reporter systems as independent measures of GSK3 activity

When reporting results, explicitly state which antibody was used, its epitope, and validation method to facilitate interpretation and reproducibility in the scientific community.

What methodological considerations are important when using GSK3A/GSK3B antibodies for immunoprecipitation experiments?

Immunoprecipitation (IP) with GSK3A/GSK3B antibodies requires careful methodology to ensure specificity and efficiency:

Antibody selection:

• Choose antibodies validated for IP applications. For isoform-specific experiments, select antibodies like 12B2 that specifically immunoprecipitate GSK3β only, or 15C2 that pulls down both GSK3α and β .

• Consider using antibodies targeting different epitopes for confirmation, as epitope accessibility may vary with protein interactions.

Lysis conditions:

• Use lysis buffers that preserve protein-protein interactions if studying complexes

• For kinase activity following IP, ensure buffer components don't inhibit kinase function

• Include appropriate phosphatase inhibitors to preserve phosphorylation status

• Consider detergent selection carefully: NP-40 or Triton X-100 (0.5-1%) maintain most interactions, while stronger detergents may disrupt them

IP protocol optimization:

• Antibody coupling: For cleaner results, couple antibodies to beads before sample addition

• Pre-clearing: Remove non-specific binding proteins by pre-incubating lysate with beads alone

• Antibody concentration: Titrate antibody amount to maximize specific pull-down while minimizing non-specific binding

• Incubation conditions: Optimize time and temperature (typically 2-16 hours at 4°C)

• Washing stringency: Balance between removing non-specific proteins and retaining specific interactions

Essential controls:

• Input control: Save an aliquot of starting material to compare with IP results

• Non-immune IgG: Use matched isotype control (e.g., mouse IgG for mouse monoclonal antibodies) to identify non-specific binding

• Post-IP supernatant: Analyze to determine IP efficiency

• Reciprocal IP: If studying interactions, confirm by IP with antibodies against the interacting partner

Downstream applications:

• Western blotting: Use antibodies targeting different epitopes than the IP antibody

• Kinase assays: Include substrate controls and specific inhibitors to confirm specificity

• Mass spectrometry: Include abundant protein controls to normalize across samples

These methodological considerations are critical for obtaining reliable and reproducible results in GSK3A/GSK3B immunoprecipitation experiments.

How can GSK3A/GSK3B antibodies be used to study dynamic changes in GSK3 activity in live cells or tissues?

Studying dynamic GSK3 activity changes requires sophisticated approaches combining antibodies with advanced imaging and biochemical techniques:

Fixed-timepoint approaches:

• Phospho-specific immunofluorescence: Use antibodies against phospho-S9 GSK3β or phospho-S21 GSK3α with quantitative imaging to measure activation state across cell populations at defined timepoints .

• Proximity ligation assay (PLA): Detect interactions between GSK3 and substrates or regulatory proteins with single-molecule sensitivity.

• Tissue section analysis: Apply phospho-specific antibodies to tissue sections collected at different timepoints to map activation patterns during development or disease progression.

Near-real-time approaches:

• FRET-based reporters: Design fluorescent protein fusions with GSK3 substrates that change conformation upon phosphorylation, then use antibodies to validate reporter accuracy.

• Bioluminescence resonance energy transfer (BRET): Similar to FRET but uses luciferase and fluorescent protein pairs for improved signal-to-noise ratio.

• Split-luciferase complementation: Create complementary fragments of luciferase fused to GSK3 and substrate to monitor interactions.

Biochemical dynamics:

• Phos-tag™ gel electrophoresis: Combined with western blotting using total GSK3 antibodies to separate and quantify different phosphorylation states.

• Microfluidic pulse-chase analysis: Rapidly change cellular conditions and fix cells at precise intervals for antibody-based detection.

• Phosphoproteomics: Quantitative mass spectrometry with antibody-based enrichment of GSK3 substrates.

Advanced microscopy applications:

• Fast confocal microscopy: For monitoring translocation of fluorescently-labeled GSK3 in response to stimuli.

• Super-resolution microscopy: Combined with highly specific antibodies to visualize nanoscale GSK3 signaling complexes.

• Correlative light and electron microscopy (CLEM): Use fluorescent antibodies to locate GSK3 activity zones, then examine ultrastructure.

Validation approaches:

• Pharmacological manipulation: Use GSK3 inhibitors with different mechanisms to confirm antibody specificity in detecting activity changes.

• Genetic manipulation: Create systems with altered phosphorylation sites to validate antibody responses.

• Quantitative analysis: Implement computational approaches to extract kinetic parameters from imaging data.

These techniques enable researchers to map the spatiotemporal dynamics of GSK3 activity in biological systems with high resolution.

What experimental design is optimal for comparing the roles of GSK3A versus GSK3B in disease models?

Optimal experimental design for comparing GSK3A versus GSK3B roles in disease models requires a comprehensive strategy:

Genetic manipulation approaches:

• Parallel single isoform models:

  • Generate matched GSK3A-specific and GSK3B-specific knockout/knockdown models

  • Compare against wild-type and double knockdown controls

  • Use tissue/cell-specific conditional systems to avoid developmental complications

  • Include rescue experiments with wild-type and kinase-dead versions of each isoform

• Dose-dependent analysis:

  • Create hypomorphic alleles or titrate knockdown efficiency

  • Evaluate dose-response relationships for each isoform

  • Use inducible systems to control timing and duration of manipulation

Analytical methods:

• Multi-parametric phenotyping:

  • Assess multiple disease-relevant endpoints in parallel

  • Apply standardized protocols across all genetic models

  • Include age-matched controls and temporal progression analysis

• Cross-platform validation:

  • Combine antibody-based detection (Western blots, IHC, IF) with functional assays

  • Validate key findings with independent methodologies

  • Include phosphorylation-specific antibodies to track activation state

Isoform-specific analysis:

• Interactome mapping:

  • Use isoform-specific antibodies for immunoprecipitation followed by mass spectrometry

  • Identify differential binding partners in disease versus normal state

  • Validate key interactions with co-IP and proximity ligation assays

• Substrate profiling:

  • Develop phosphoproteomic workflows with isoform-specific knockdowns

  • Identify preferential substrates for each isoform

  • Validate with in vitro kinase assays using immunoprecipitated GSK3A or GSK3B

Pharmacological approaches:

• Isoform-biased inhibitors:

  • Use available compounds with preference for one isoform

  • Compare with pan-GSK3 inhibitors

  • Combine with genetic approaches for validation

• Temporal intervention studies:

  • Apply inhibitors at different disease stages

  • Track isoform-specific activation using phospho-specific antibodies

  • Correlate with disease progression markers

Translational relevance:

• Human sample analysis:

  • Analyze isoform expression and activation in patient samples

  • Correlate with disease severity and progression

  • Use immunohistochemistry to map spatial distribution changes

• Biomarker development:

  • Assess isoform-specific phosphorylation as potential biomarkers

  • Evaluate isoform ratio changes during disease progression

  • Correlate with treatment response

This comprehensive experimental design allows for robust comparison of GSK3A versus GSK3B roles while minimizing confounding factors and maximizing translational relevance.

What are the key differences between monoclonal and polyclonal GSK3A/GSK3B antibodies for specific research applications?

Monoclonal and polyclonal GSK3A/GSK3B antibodies offer distinct advantages and limitations for different research applications:

Monoclonal Antibodies:

Advantages:

• High specificity: Monoclonal antibodies like 12B2 and 15C2 can distinguish between closely related epitopes, such as the nonphosphorylated versus phosphorylated forms of GSK3 .

• Consistency: Production from a single hybridoma clone ensures lot-to-lot reproducibility.

• Isoform discrimination: Can be developed to specifically target GSK3A or GSK3B, as with 12B2 which is specific for nonphospho-S9 GSK3β .

• Clean signal: Typically produce less background in applications like immunohistochemistry and immunofluorescence.

Optimal applications:

• Quantitative Western blotting: Where consistent binding characteristics are critical

• Immunoprecipitation: When targeting specific isoforms (e.g., 12B2 for GSK3β only)

• Flow cytometry: Where signal-to-noise ratio is crucial

• ELISA: Where standardized performance is essential

Examples:

• E-11 monoclonal targets C-terminal epitope (aa 345-420) of human GSK3β

• 7/GSK-3b mouse recombinant monoclonal

• 12B2 monoclonal specific for nonphospho-S9 GSK3β

Polyclonal Antibodies:

Advantages:

Optimal applications:

• Immunohistochemistry: Where signal amplification is beneficial

• Chromatin immunoprecipitation: Where epitope accessibility may be limited

• Detection of modified proteins: Where post-translational modifications might alter some epitopes

• Protein detection in fixed tissues: Where antigen retrieval may not fully restore all epitopes

Examples:

• ab131356 rabbit polyclonal targeting aa 1-50 of human GSK3B

• GTX133372 rabbit polyclonal for cytoplasmic detection

Application-specific considerations:

When designing experiments, researchers should select antibodies based on their specific requirements for specificity, sensitivity, and application compatibility.

How do sample preparation methods affect the detection of GSK3A/GSK3B phosphorylation states?

Sample preparation significantly impacts the detection of GSK3A/GSK3B phosphorylation states, potentially leading to artifacts or misinterpretation:

Protein extraction considerations:

• Buffer composition:

  • Phosphatase inhibitors: Critical for preserving phosphorylation—must include both serine/threonine (e.g., sodium fluoride, β-glycerophosphate) and tyrosine phosphatase inhibitors (e.g., sodium orthovanadate) .

  • Detergent selection: NP-40 or Triton X-100 preserve most phosphorylation states; harsher detergents like SDS may affect antibody epitope recognition.

  • Protease inhibitors: Essential to prevent degradation that might remove phosphorylated regions.

  • pH considerations: Phosphorylation stability is pH-dependent; maintain pH ~7.4 during extraction.

• Physical disruption methods:

  • Temperature control: Keep samples cold (4°C) throughout processing to minimize phosphatase activity.

  • Homogenization technique: Gentler methods may better preserve protein complexes that protect phosphorylation sites.

  • Processing time: Minimize time between tissue collection and protein denaturation.

Western blotting considerations:

• Sample handling:

  • Freeze-thaw cycles: Minimize as they can activate phosphatases.

  • Loading buffer composition: β-mercaptoethanol concentration affects epitope accessibility.

  • Heating conditions: Boiling time can affect phospho-epitope detection.

• Gel and transfer parameters:

  • Gel percentage: Higher percentage gels better resolve phosphorylated from non-phosphorylated forms.

  • Phos-tag™ supplements: Consider for enhanced separation of phosphorylated species.

  • Transfer conditions: Phosphorylated proteins may require optimized transfer parameters.

Immunohistochemistry/immunofluorescence considerations:

• Fixation methods:

  • Paraformaldehyde concentration: 2-4% typically preserves phospho-epitopes.

  • Fixation duration: Overfixation can mask phospho-epitopes.

  • Post-fixation washes: Critical for removing excess fixative.

• Antigen retrieval:

  • Heat-induced epitope retrieval: Temperature and pH optimization crucial for phospho-epitopes.

  • Buffer composition: Citrate (pH 6.0) versus EDTA (pH 9.0) can differentially affect epitope accessibility.

  • Enzymatic retrieval: May remove some phosphorylation marks.

Verification strategies:

• Controlled manipulation:

  • Phosphatase treatment: Samples treated with alkaline phosphatase serve as negative controls .

  • Kinase treatment: Samples treated with Akt1 to increase phosphorylation serve as positive controls .

  • Pharmacological manipulation: GSK3 inhibitor treatment of cells prior to collection.

• Technical controls:

  • Internal controls: Include proteins with stable phosphorylation as processing quality indicators.

  • Sample splitting: Process identical samples with different methods to assess impact.

  • Parallel detection methods: Combine antibody detection with mass spectrometry-based phospho-detection.